Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enasidenib for CCUS with IDH2 Mutations
NCT06240754Phase 2Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2024
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of enasidenib in clonal cytopenia of undetermined significance (CCUS), sponsored by Washington University School of Medicine. Started Oct 2024; status: recruiting.
02
Drugs
enasidenib
03
Conditions
clonal cytopenia of undetermined significance (CCUS)
Beyond the preview
Go deeper on NCT06240754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06240754.